GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GGNNQ) » Definitions » Degree of Operating Leverage

GGNNQ (Genocea Biosciences) Degree of Operating Leverage : 0.00 (As of Mar. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Genocea Biosciences Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Genocea Biosciences's Degree of Operating Leverage for the quarter that ended in Mar. 2022 was 0.00. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Genocea Biosciences's Degree of Operating Leverage or its related term are showing as below:

GGNNQ's Degree of Operating Leverage is not ranked *
in the Biotechnology industry.
Industry Median: -0.02
* Ranked among companies with meaningful Degree of Operating Leverage only.

Genocea Biosciences Degree of Operating Leverage Historical Data

The historical data trend for Genocea Biosciences's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Degree of Operating Leverage Chart

Genocea Biosciences Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genocea Biosciences Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genocea Biosciences's Degree of Operating Leverage

For the Biotechnology subindustry, Genocea Biosciences's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genocea Biosciences's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Genocea Biosciences's Degree of Operating Leverage falls into.


;
;

Genocea Biosciences Degree of Operating Leverage Calculation

Genocea Biosciences's Degree of Operating Leverage for the quarter that ended in Mar. 2022 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -36.118 (Mar. 2022) / -41.444 (Mar. 2021) - 1 )/( 1.911 (Mar. 2022) / 1.359 (Mar. 2021) - 1 )
=-0.1285/0.4062
=-0.32***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Genocea Biosciences  (OTCPK:GGNNQ) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Genocea Biosciences Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Genocea Biosciences Business Description

Traded in Other Exchanges
N/A
Address
100 Acorn Park Drive, Cambridge, MA, USA, 02140
Genocea Biosciences Inc is a USA-based biopharmaceutical company discovering and developing novel cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens , that drive pro-tumor immune responses.
Executives
John Lunger director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Jennifer Lyn Herron director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jacquelyn L Sumer officer: CHIEF LEGAL & COMPLIANCE OFF C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Stapleton Raymond D Jr officer: EVP PHARM SCI & MFG C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Gisela Schwab director 6701 KAISER DRIVE, FREMONT CA 94555
Diantha Duvall officer: CHIEF FINANCIAL OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Girish N Aakalu officer: CHIEF BUSINESS OFFICER C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Narinderjeet Singh officer: SENIOR VP, PS&M C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Pamela Carroll officer: SVP IMMUNO-ONCOLOGY C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Thomas Andrew Davis officer: CHIEF MEDICAL OFFICER 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Derek M Meisner officer: SENIOR VP AND GENERAL COUNSEL C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Michael Alfieri officer: Principle Financial Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Howard Mayer director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Cooper Ronald Harold Wilfred director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140

Genocea Biosciences Headlines

From GuruFocus

Q1 2019 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

By GuruFocusNews GuruFocusNews 06-03-2022

Q3 2020 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q2 2020 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Genocea Biosciences, Inc. - Special Call Transcript

By GuruFocus Research 02-13-2024

Q1 2021 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q2 2019 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q3 2021 Genocea Biosciences Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024